Journal of Stroke & Cerebrovascular Diseases
Volume 18, Issue 1 , Pages 23-27 , January 2009

Ancrod for Acute Ischemic Stroke: A New Dosing Regimen Derived from Analysis of Prior Ancrod Stroke Studies

  • David E. Levy, MD

      Affiliations

    • Neurobiological Technologies Inc, Edgewater, New Jersey
    • Corresponding Author InformationAddress correspondence to David E. Levy, MD, Neurobiological Technologies Inc, 115 River Rd (Suite 171), Edgewater, NJ 07020.
    • ,
  • James Trammel, MS

      Affiliations

    • i3Statprobe, Stonewall, Louisiana
    • ,
  • Warren W. Wasiewski, MD

      Affiliations

    • Neurobiological Technologies Inc, Edgewater, New Jersey
    • ,
  • for the Ancrod Stroke Program (ASP) Study Team

Received 6 May 2008 ,Revised 18 June 2008 ,Accepted 1 July 2008.

References 

  1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1587
  2. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: The NINDS rt-PA stroke study. Neurology. 2000;55:1649–1655
  3. Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association stroke council, clinical cardiology council, cardiovascular radiology and intervention council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups; the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655–1711
  4. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset, the ATLANTIS study: A randomized controlled trial; alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA. 1999;282:2019–2026
  5. Donnan GA. A new roadmap for neuroprotection. Stroke. 2008;39:242–248
  6. The Ancrod Stroke Study Investigators. Ancrod for the treatment of acute ischemic brain infarction. Stroke. 1994;25:1755–1759
  7. Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke, the STAT study: A randomized controlled trial; stroke treatment with ancrod trial. JAMA. 2000;283:2395–2403
  8. Hennerici MG, Kay R, Bogousslavsky J. et al, for the ESTAT Investigators. Intravenous ancrod for acute ischemic stroke in the European stroke treatment with ancrod trial: A randomized controlled trial. Lancet. 2006;368:1871–1888
  9. Dempfle CE, Argiriou S, Alesci S, et al. Fibrin formation and proteolysis during ancrod treatment: Evidence for des-A-profibrin formation and thrombin independent factor XIII activity. Ann N Y Acad Sci. 2001;936:210–214
  10. Levy DE, del Zoppo GJ. Ancrod: A potential treatment for acute, ischemic stroke from snake venom. Toxin Rev. 2006;25:319–329
  11. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol. 1957;17:237–246
  12. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley and Sons; 1989;
  13. Olinger CP, Brott TG, Barsan WG, et al. Use of ancrod in acute or progressing ischemic cerebral infarction. Ann Emerg Med. 1988;17:1208–1209
  14. Kannel WB, D'Agostino RB, Belanger AJ. Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol. 1992;2:457–466
  15. Lee AJ, Lowe GD, Woodward M, et al. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: The Scottish heart health study. Br Heart J. 1993;69:338–342
  16. Qizilbash N, Jones L, Warlow C, et al. Fibrinogen and lipid concentrations as risk factors for transient ischemic attacks and minor ischemic strokes. BMJ. 1991;303:605–609
  17. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501–505

 Data and analytical resources used in preparing this manuscript were provided by the current sponsor of ancrod, Neurobiological Technologies Inc.

 Drs. Levy and Wasiewski are employees of and Mr. Trammel is a contractor for Neurobiological Technologies Inc.

PII: S1052-3057(08)00152-3

doi: 10.1016/j.jstrokecerebrovasdis.2008.07.009

Journal of Stroke & Cerebrovascular Diseases
Volume 18, Issue 1 , Pages 23-27 , January 2009

Article Tools

* Image Usage & Resolution